EP3452046A4 - CANNABIDIOL USED TO REDUCE A STEROID DOSE AND TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES - Google Patents
CANNABIDIOL USED TO REDUCE A STEROID DOSE AND TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES Download PDFInfo
- Publication number
- EP3452046A4 EP3452046A4 EP17792603.7A EP17792603A EP3452046A4 EP 3452046 A4 EP3452046 A4 EP 3452046A4 EP 17792603 A EP17792603 A EP 17792603A EP 3452046 A4 EP3452046 A4 EP 3452046A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cannabidiol
- reducing
- autoimmune diseases
- treating inflammatory
- steroid dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title 1
- 229950011318 cannabidiol Drugs 0.000 title 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/143,694 US9889100B2 (en) | 2013-05-02 | 2016-05-02 | Cannabidiol for treatment of severe and refractory graft-versus-host disease |
| PCT/IL2017/050483 WO2017191630A1 (en) | 2016-05-02 | 2017-05-01 | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3452046A1 EP3452046A1 (en) | 2019-03-13 |
| EP3452046A4 true EP3452046A4 (en) | 2020-02-19 |
Family
ID=60203614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17792603.7A Pending EP3452046A4 (en) | 2016-05-02 | 2017-05-01 | CANNABIDIOL USED TO REDUCE A STEROID DOSE AND TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3452046A4 (ko) |
| KR (1) | KR102537990B1 (ko) |
| CN (2) | CN109414443A (ko) |
| AU (1) | AU2017260873B2 (ko) |
| CA (1) | CA3022900A1 (ko) |
| IL (1) | IL262713B1 (ko) |
| WO (1) | WO2017191630A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220347096A1 (en) | 2019-10-03 | 2022-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal cannabinoids and uses thereof |
| WO2021117016A1 (en) * | 2019-12-13 | 2021-06-17 | Buzzelet Development And Technologies Ltd. | Compositions and methods for treatment of inflammation with steroids and a modulator |
| JP2023516284A (ja) * | 2020-02-19 | 2023-04-19 | マーチャント，シュリーマ | カンナビジオールの組成物および治療的使用 |
| EP4208164A1 (en) * | 2020-09-06 | 2023-07-12 | Medicane Research & Development Ltd. | Composition comprising cannabinoids, and/or terpens, and methods of using same |
| CN113398104B (zh) * | 2021-07-14 | 2022-04-08 | 北京森宏健康科技有限公司 | 大麻二酚在治疗胆红素脑病中的用途 |
| WO2023058016A1 (en) * | 2021-10-04 | 2023-04-13 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) | Non-steroidal anti-inflammatory drugs and cannabinoids and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0203437A3 (en) * | 1999-03-22 | 2003-07-28 | Immugen Pharmaceuticals Inc So | Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases |
| US20070060638A1 (en) * | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
| US8242178B2 (en) * | 2007-06-18 | 2012-08-14 | University Of South Carolina | Use of cannabidiol in the treatment of autoimmune hepatitis |
| US9623000B2 (en) * | 2008-07-31 | 2017-04-18 | Dekel Pharmaceuticals Ltd | Compositions and methods for treating inflammatory disorders |
-
2017
- 2017-05-01 AU AU2017260873A patent/AU2017260873B2/en active Active
- 2017-05-01 CN CN201780040985.2A patent/CN109414443A/zh active Pending
- 2017-05-01 KR KR1020187034907A patent/KR102537990B1/ko active IP Right Grant
- 2017-05-01 EP EP17792603.7A patent/EP3452046A4/en active Pending
- 2017-05-01 CN CN202311190299.7A patent/CN117017998A/zh active Pending
- 2017-05-01 CA CA3022900A patent/CA3022900A1/en active Pending
- 2017-05-01 WO PCT/IL2017/050483 patent/WO2017191630A1/en unknown
- 2017-05-01 IL IL262713A patent/IL262713B1/en unknown
Non-Patent Citations (1)
| Title |
|---|
| VENKATESH L. HEGDE ET AL: "Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental Autoimmune Hepatitis Following Activation of TRPV1 Receptors by Cannabidiol", PLOS ONE, vol. 6, no. 4, 1 April 2011 (2011-04-01), pages e18281, XP055654715, DOI: 10.1371/journal.pone.0018281 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017260873A1 (en) | 2018-11-29 |
| IL262713A (en) | 2018-12-31 |
| WO2017191630A1 (en) | 2017-11-09 |
| KR20190016952A (ko) | 2019-02-19 |
| CA3022900A1 (en) | 2017-11-09 |
| AU2017260873B2 (en) | 2023-03-02 |
| KR102537990B1 (ko) | 2023-05-30 |
| CN117017998A (zh) | 2023-11-10 |
| CN109414443A (zh) | 2019-03-01 |
| IL262713B1 (en) | 2024-03-01 |
| EP3452046A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3731849A4 (en) | EXOSOME FOR IMMUNONCOLOGICAL AND ANTI-INFLAMMATORY THERAPY | |
| EP3723853A4 (en) | SYSTEMS AND PROCEDURES FOR OPERATING PHOTOTHERAPY KIOSKES | |
| EP3452046A4 (en) | CANNABIDIOL USED TO REDUCE A STEROID DOSE AND TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | |
| EP3275442A4 (en) | Therapeutic agent for bile duct cancer | |
| EP3634442A4 (en) | METHODS OF TREATMENT AND PREVENTION OF DISEASES | |
| EP3399972A4 (en) | LOW DOSE THERAPEUTIC TREATMENT | |
| EP3347368A4 (en) | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | |
| EP3169260A4 (en) | Methods and systems for treating diabetes and related diseases and disorders | |
| EP3215076A4 (en) | A method and device for external urinary incontinence treatment for women | |
| SI3310389T1 (sl) | Topični sestavki, ki obsegajo kortikosteroid in retinoid za zdravljenje psoriaze | |
| EP3731832A4 (en) | CANNABINOID DOSAGE FORM | |
| EP3313331A4 (en) | MECHANISM FOR EFFICIENTLY SINGING AND REMOVING AN EXOSQUELET | |
| EP3148575A4 (en) | Methods and compositions for treating allergy and inflammatory diseases | |
| EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
| EP3592345A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | |
| EP3344258A4 (en) | TREATMENT OF AUTOIMMUNE DISEASES AND AUTO IGNITION DISEASES | |
| EP3192875A4 (en) | Sustained-release pharmaceutical composition for treating and preventing ophthalmic diseases | |
| EP3122743A4 (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP3411399A4 (en) | SYNERGISTIC DRUG-MEDICINAL SYNERGY TECHNOLOGY FOR THE TREATMENT OF DISEASES | |
| EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
| EP3672434A4 (en) | DIAPER SYSTEM AND FLAP | |
| EP3364965A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES | |
| EP3304086A4 (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| EP3120852A4 (en) | Prophylactic and/or therapeutic agent for immune diseases | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20181122 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20200116 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/00 20060101ALI20200110BHEP Ipc: A61P 29/00 20060101ALI20200110BHEP Ipc: A61K 31/573 20060101ALI20200110BHEP Ipc: A61P 1/16 20060101ALI20200110BHEP Ipc: A61K 31/352 20060101ALI20200110BHEP Ipc: A61K 31/56 20060101AFI20200110BHEP Ipc: A61K 31/05 20060101ALI20200110BHEP Ipc: A61K 45/06 20060101ALI20200110BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210528 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |